Silexion Therapeutics Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLXN research report →
Price Chart
About the company
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor.
- CEO
- Ilan Hadar
- IPO
- 2024
- Employees
- 14
- HQ
- Jerusalem, TA, IL
Get TickerSpark's AI analysis on SLXN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $110.11K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 4.11
- EV/EBITDA
- 0.05
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -563.11%
- ROIC
- 628.40%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $11.63M
- Net Income
- $-11,912,000+27.6%
- EPS
- $-89.60+97.7%
- OCF Growth
- -28.9%
- FCF Growth
- -28.6%
- 52W High
- $42.00
- 52W Low
- $0.24
- 50D MA
- $0.72
- 200D MA
- $8.75
- Beta
- -0.25
- RSI (14)
- 35
- Avg Volume
- 10.00M
No earnings-call transcripts are available for SLXN yet.
- Free Float
- 99.0%
- Shares Outstanding
- 419.00K
- Float Shares
- 414.62K
of shares held by institutions
6 13F filers
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 4, 26 | Shirvan Mitchell | other | 6,000 |
| Jun 4, 26 | Horenshtein Hadar Mirit | other | 7,500 |
| Jun 4, 26 | Hadar Ilan | other | 10,000 |
| Mar 26, 26 | Shirvan Mitchell | sell | 22,818 |
| Feb 20, 26 | Noy Shlomo | other | 9,091 |
| Feb 20, 26 | Noy Shlomo | other | 10,685 |
| Feb 20, 26 | Alon Ruth | other | 10,685 |
| Feb 20, 26 | Alon Ruth | other | 9,091 |
| Feb 20, 26 | Shirvan Mitchell | other | 49,726 |
| Feb 20, 26 | Horenshtein Hadar Mirit | other | 49,726 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SLXN coverage
Recent articles, reports, and earnings notes.
No research on SLXN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SLXN report →Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
globenewswire.com · Sep 30
Silexion Therapeutics Announces Exercise of Warrants
globenewswire.com · Sep 29
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
globenewswire.com · Sep 28
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
globenewswire.com · Sep 9
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 14
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
globenewswire.com · Aug 11
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers
globenewswire.com · Aug 4
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
globenewswire.com · Jul 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.